Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1979-9-25
|
| pubmed:abstractText |
The antimetabolite 6-azauridine blocks the de novo synthesis of pyrimidines and causes increased serum levels of several amino acids including homocystine. 6-Azauridine was was withdrawn from clinical use for the treatment of psoriasis because of the occurence of arterial and venous thromboembolic episodes in some psoriatic patients. Utilizing a standard animal model for the recognition of venous and arterial thrombosis, 6-azauridine was demonstrated in this study to cause thrombosis without producing homocystinemia when administered orally or intravenously.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0301-0147
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
54-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:456945-Administration, Oral,
pubmed-meshheading:456945-Animals,
pubmed-meshheading:456945-Azauridine,
pubmed-meshheading:456945-Blood Coagulation,
pubmed-meshheading:456945-Dose-Response Relationship, Drug,
pubmed-meshheading:456945-Injections, Intravenous,
pubmed-meshheading:456945-Male,
pubmed-meshheading:456945-Rabbits,
pubmed-meshheading:456945-Thrombosis
|
| pubmed:year |
1979
|
| pubmed:articleTitle |
The thrombogenicity of 6-azouridine.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|